The upgrade centres on new machinery and advanced technology designed to expand capacity and sharpen turnaround times in increasingly competitive flexible packaging markets.
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The first of four planned modules at the new plant is expected to come online by summer 2026
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
Subscribe To Our Newsletter & Stay Updated
